These proofs of concept of ncRNA-based therapeutics combined with the accruing evidence for the tumor-suppressive effects of miRNA-mediated inhibition of FAK and/or PYK2 suggest that the development of FAK- and/or PYK2-specific anti-cancer mi/siRNA therapies would be worthwhile. Here, PTK2B is linked to neoplasm.